Home » Newsletters » BioWorld Science

BioWorld Science

Aug. 10, 2010

View Archived Issues

Trophos claims new cytoprotective agents

Scynexis discloses new antiviral cyclosporin A derivatives

NeuroSearch discovers new anticonvulsant agents

Cannabidiol displays antiangiogenic activity in preclinical tests

RGS1, IL12A and MPHOSPH9/CDK2AP1 gene SNPs are linked to susceptibility to MS

CONDOR data disclosed on GI safety of celecoxib vs. diclofenac/omeprazole in arthritis

Aragon doses first patient in phase I/II ARN-509 trial in prostate cancer

Vectura and GSK sign license agreement for dry powder drug formulations

Pluristem presents preclinical in vivo data on PLX cell therapy for pain

FDA seeks injunction against Regenerative Sciences for cultured cell product

Celgene's pomalidomide receives E.U. orphan drug status for myelofibrosis

Nabilone shows promise to treat cannabis use disorders

Curis provides update on phase II vismodegib trial in advanced ovarian cancer

Obeticholic acid receives E.U. orphan drug status for primary biliary cirrhosis

SNS-032 shows moderate activity in phase I trial in B-cell malignancies

European researchers describe new Aurora kinase A inhibitors

EMA grants octenidine orphan drug status for sepsis in premature infants

Daiichi Sankyo presents new agents for treatment of osteoporosis

HBGF-1-coated biodegradable device receives E.U. orphan drug status for spinal cord injury

Repros receives positive feedback on Androxal from FDA

Teva Pharma reports on rasagiline in early Parkinson's disease

Tranilast obtains orphan drug status for prevention of scarring in glaucoma surgery

Endo submits NDA for crush-resistant oxymorphone to FDA and plans to acquire Penwest

Amarin advances phase III AMR-101 trials in patients with high trigliceride levels

GSK and Genmab report topline data on ofatumumab in chronic lymphocytic leukemia